Adlai Nortye’s (ANL) Buy Rating Reiterated at HC Wainwright

Adlai Nortye (NASDAQ:ANL)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $9.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 189.39% from the stock’s previous close.

Adlai Nortye Price Performance

NASDAQ ANL opened at $3.11 on Monday. The company’s 50-day simple moving average is $2.15 and its two-hundred day simple moving average is $4.61. Adlai Nortye has a one year low of $1.85 and a one year high of $17.48.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.